Volume | 195,911 |
|
|||||
News | - | ||||||
Day High | 45.74 | Low High |
|||||
Day Low | 43.785 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Amphastar Pharmaceuticals Inc | AMPH | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
45.42 | 43.785 | 45.74 | 45.74 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,424 | 195,911 | $ 44.44 | $ 8,706,297 | - | 26.76 - 67.66 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:29:47 | 1 | $ 44.54 | USD |
Amphastar Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.18B | 48.86M | - | 498.99M | 91.39M | 1.87 | 23.82 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Amphastar Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AMPH Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 45.88 | 48.06 | 43.785 | 46.17 | 424,447 | -1.33 | -2.9% |
1 Month | 54.40 | 54.40 | 43.785 | 46.87 | 651,891 | -9.85 | -18.11% |
3 Months | 56.94 | 67.66 | 43.785 | 52.66 | 467,860 | -12.39 | -21.76% |
6 Months | 37.50 | 67.66 | 35.62 | 49.17 | 455,945 | 7.05 | 18.8% |
1 Year | 28.37 | 67.66 | 26.76 | 43.02 | 349,852 | 16.18 | 57.03% |
3 Years | 20.30 | 67.66 | 16.91 | 33.26 | 307,869 | 24.25 | 119.46% |
5 Years | 19.12 | 67.66 | 12.325 | 28.75 | 274,787 | 25.43 | 133.0% |
Amphastar Pharmaceuticals Description
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. |